Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22640159 | 1.00 | CYP2D6 (0.74) | CYP2D6HTTMEN1KMT2AMAPT | |
| SCHEMBL10790889 | 0.87 | CYP2D6 (0.74) | CYP2D6HTTMEN1KMT2AADRB2 | |
| SCHEMBL22639888 | 0.86 | PKM (0.63) | CYP2D6HTTMEN1KMT2ANPC1 | |
| SCHEMBL22639720 | 0.86 | PKM (0.63) | CYP2D6HTTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL11226403 | 0.86 | CYP2D6 (0.72) | CYP2D6HTTMEN1KMT2AMAPT | |
| SCHEMBL6643064 | 0.86 | CYP2D6 (0.72) | CYP2D6HTTMEN1KMT2AMAPT | |
| SCHEMBL11346808 | 0.86 | CYP2D6 (0.72) | CYP2D6HTTMEN1KMT2AMAPT | |
| SCHEMBL10774437 | 0.86 | CYP2D6 (0.72) | CYP2D6HTTMEN1KMT2AMAPT | |
| SCHEMBL22957897 | 0.85 | CYP2D6 (1.00) | CYP2D6HTTMEN1KMT2AMAPT | |
| SCHEMBL11762303 | 0.83 | CYP2D6 (0.68) | CYP2D6HTTMEN1KMT2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | CYP2D6 3360/4885HTT 488/4885MEN1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.